This site is intended for US healthcare professionals

This site is intended for US healthcare professionals

Decorative flipped Main visual
Ordering Information

For support with ordering, please contact your dedicated representative

80 MG/4 ML (80 MG KIT) NDC 70710-2091-3

Cardinal Specialty
Cencora (ASD)
McKesson Plasma & Biologics
McKesson Specialty
Oncology Supply
6055446
10304417
3063427
5021363
10304486

(Kits include Beizray + Albumin)

80 MG/4 ML x 2 (160 MG KIT) NDC 70710-2093-4

Cardinal Specialty
Cencora (ASD)
McKesson Plasma & Biologics
McKesson Specialty
Oncology Supply
6055453
10304461
3063435
5011364
10304439

(Kits include Beizray + Albumin)

20 MG/ML (20 MG VIAL) NDC 70710-2092-8

Cardinal Specialty
Cencora (ASD)
McKesson Plasma & Biologics
McKesson Specialty
Oncology Supply
6099717
10305986
3074747
5021954
10306082
Regional Beizray support

[Selected State]

Select State

State Representative

[State representative]
[email address]

Field Reimbursement Manager

[Field Reimbursement Manager]
[email address]

Beizray has National
Medicare MAC Coverage

[Mac region]

image/svg+xml
Regional Beizray support

Zydus and its agents make no guarantee regarding reimbursement for any service or item. The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. For eligibility requirements, please contact a patient assistance specialist.

 

To report adverse events or product complaints please email medicalaffairs@zydususa.com,
call 877-993-8779, or fax +1-609-559-0699 or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATIONS AND IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID
RETENTION

  • Treatment-related mortality associated with BEIZRAY is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive BEIZRAY as a single agent at a dose of 100 mg/m2.
  • Avoid the use of BEIZRAY in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 x ULN concomitant with alkaline phosphatase >2.5 x ULN.Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death.Patients with isolated elevations of transaminase >1.5 x ULN also had a higher rate of febrile neutropenia.Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of BEIZRAY.
  • Do not administer BEIZRAY to patients with neutrophil counts of <1500 cells/mm3. Monitor blood counts frequently as neutropenia may be severe and result in infection.
  • Do not administer BEIZRAY to patients who have a history of severe hypersensitivity reactions to BEIZRAY.Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the BEIZRAY infusion and administration of appropriate therapy.
  • Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites).
Image